The use of circulating microRNAs as diagnostic biomarkers in colorectal cancer

Cancer Biomarkers

Volumn 15, Issue 2, 2015, Pages 103-113

  Clancy, Cillian ^a   Joyce, Myles R ^b   Kerin, Michael J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

circulating; Colorectal; microRNA

Indexed keywords

MICRORNA; MICRORNA 143 5P; MICRORNA 18A 5P; MICRORNA 21 5P; MICRORNA 29A 5P; MICRORNA 378 5P; UNCLASSIFIED DRUG; TUMOR MARKER;

COLORECTAL CANCER; DISEASE MARKER; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RNA ANALYSIS; SYSTEMATIC REVIEW; BLOOD; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; GENE EXPRESSION REGULATION; GENETICS; META ANALYSIS;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS;

EID: 84925351996     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-140456     Document Type: Review

References (70)

1. World Cancer Research Fund and American Institute for Cancer Research Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research, 2007.
2. Kim YW, Kim IY. The role of surgery for asymptomatic primary tumours in unresectable stage IV colorectal cancer. Ann Coloproctol. 2013; 29(2): 44-54.
3. O'Connell JB, MAggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004; 96: 1420-5.
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61: 759-67.
5. Alberici P. The Adenoma-Carcinoma sequence in colorectal cancer: Scratching the surface (Doctoral Thesis). 2007-04-20. repub.eur.nl/pub/9785/.
6. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: A decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149: 659-69.
7. Wu WK, Law PT, Lee CW, Cho CH, Fan D, Wu K, Yu J, Sung JJ. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis. 2011; 32(3): 247-53.
8. Yu W et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature. 2008; 451: 202-206.
9. Dong XY et al. Implication of snoRNA U50 in human breast cancer. J Genet Genomics. 2009; 36: 447-454.
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-233.
11. Chiang HR, Schoenfeld LW, Ruby JG et al. Mammalian microRNAs: Experimental evaluation of novel and previously annotated genes. Genes Dev. 2010; 24: 992-1009.
12. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 2008; 9(2): 102-114.
13. Ambros V. The functions of animal microRNAs. Nature. 2004: 431(7006): 350-355.
14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism and function. Cell. 2004; 116(2): 281-297
15. Ameida MI, Reis RM, Calin GA. MicroRNA history: Discovery, recent applications and next frontiers. Mutat Res. 2011; 717(1-2): 1-8.
16. Carthew RW et al. Origins and mechanisms of miRNAs and siRNAs. Cell. 2009; 136: 642-655
17. A.M. Eiring, J.G. Harb, P. Neviani et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.
18. Calin GA, Dumitru CD, Shimizu et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002 Nov 26; 99(24): 15524-9.
19. McDermott AM, Heneghan HM, Miller N, Kerin MJ. The therapeutic potential of microRNAs: disease modulators and drug targets. 2011: 28(12): 3016-3029.
20. Michael MZ, O'Connor SM, van Holst Pellekaan NG et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003; 1(12): 882-91.
21. Ma Y, Zhang P, Yang J et al. Candidate microRNA biomarkers in human colorectal cancer: Systematic review profiling studies and experimental validation. 2012; 130(9): 2077-2087.
22. Healy NA, Heneghan HM, Miller N et al. Systemic miRNAs as potential biomarkers for malignancy. Int J Cancer. 2012; 131(10): 2215-22.
23. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancers and other diseases. Cell Res. 2008; 18(10): 997-1006.
24. Wu CW, Dong YJ, Liang QY et al. MicroRNA-18a Attenuates DNA Damage Repair through Suppressing the Expression of Ataxia Telangiectasia Mutated in Colorectal Cancer. PLoS ONE 2013; 8(2): e57036.
25. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005; 435: 828-833.
26. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005; 65: 9628-9632.
27. Tao J, Wu D, Li P et al. microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells. Molecular Medicine Reports. 2012; 5: 167-172.
28. Morimura R, Komatsu S, Ichikawa D et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. British Journal of Cancer. 2011; 105: 1733-1740.
29. Aslam MI, Patel M, Singh B, Jameson JS, Pringle JH. MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. J Transl Med. 2012; 10: 28.
30. Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One. 2013; 14(5): 5e62880.
31. Vega AB, Pericay C, Moya I et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep. 2013; 30(1): 320-6.
32. Giraldez MD, Lozano JJ, Ramirez G et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol. 2013; 11(6): 681-8.
33. Liu GH, Zhou ZG, Chen R et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 2013; 34(4): 2175-81.
34. Ferraro A, Kontos C, Boni T et al. Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three gene network (miR-21-ITGB4-PCDC4) as a predictor of metastatic tumour potential. Epigenetics. 2013; 22: (9)1.
35. Minard ME, Ellis LM, Gallick GE. Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis. 2006; 23(5-6): 301-13.
36. Cottonham CL, Kaneko S, Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem. 2010; 285(46): 35293-302.
37. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012; 138(10): 1659-66.
38. Kanaan Z, Rai SN, Eichenberger MR et al. Plasma miR-21: A potential diagnostic marker of colorectal cancer. Ann Surg. 2012; 256(3): 544-51.
39. Toiyama Y, Takahashi M, Hur K et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Int. 2013; 105(12): 849-59.
40. Pu XX, Huang GL, Guo HQ et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010; 25(10): 1674-80.
41. Nugent M, Miller N, Kerin MJ. Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol. 2012; 106(8): 947-52.
42. Tang W, Zhu Y, Gao J et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix-metalloproteinase-2 and E-Cadherin via KLF4.
43. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010; 127(1): 128-26.
44. Hofsli E, Sjursen W, Prestvik WS et al. Identification of serum microRNA profiles in colon cancer. Br J Cancer. 2013; 108(8): 1712-9.
45. Faltejskova P, Bocanek O, Sachlova M et al. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark. 2012; 12(4): 199-204.
46. Zanutto S, Pizzamiglio S, Ghilotti M et al. Circulating miR-378 in plasma: A reliable haemolysis-independant biomarker for colorectal cancer. Br J Cancer. 2014; 110(4): 1001-7.
47. Ng EK, Chong WW, Jin H et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut. 2009; 58(10): 1375-81
48. Wang S, Xiang J, Li Z et al. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer. 2013 Mar 2. doi: 10.1002/ijc.28136. [Epub ahead of print].
49. Pagliuca A, Valvo C, Fabrizi E et al. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a co-ordinate program of gene repression. Oncogene. 2013; 32(40): 4806-13.
50. Qian X, Yu J, Yin Y et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle. 2013; 12(9): 1385-94.
51. M Feng, Z Li, M Aau, CH Wong, X Yang, Q Yu. Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation Oncogene. 2011; 30(19): 2242-2251.
52. LT Chen, SD Xu, H Xu, JF Zhang, JF Ning, SF Wang. MicroRNA-378 is associated with non-small cell lung cancer brain metastases by promoting cell migration, invasion and tumor angiogenesis. Med Oncol. 2012; 29(3): 1673-1680.
53. Zhang GJ, Zhou H, Xiao HX, Li Y, Zhou T. MiR-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer. BMC Cancer. 2014; 14(1): 109.
54. Li H, Dai S, Zhen T et al. Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer. Eur J Cancer. 2014; 50(6): 1207-21.
55. Wang Q, Huang Z, Ni S et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One. 2012; 7(9): e44398.
56. Yong FL, Law CW, Wang CW. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer. 2013; 13: 280.
57. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 50: 298-301.
58. Mestdagh P, Hartmann N, Baeriswyl L et al. Evaluation of quantitative microRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods. 2014; 8: 809-15.
59. Pritchard CC, Crow E, Wood B et al. Blood cell origin of circulating microRNAs: A cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2012; 5(3): 492-497.
60. Yeo RWY, Lai RC, Zhang B et al. Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev. 2013; 65: 336-341.
61. Lai RC, Yeo RWY, Tan KH et al. Exosomes for drug delivery - a novel application for the mesenchymal stem cell. Biotech Adv. 2013; 31: 543-551.
62. Hannafon BN, Ding WQ. Inter-cellular communication by exosome derived microRNAs in cancer. Int J Mol Sci. 2013; 14(7): 14240-69.
63. Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalisation of the receptor. Cell. 1983; 33: 967-978.
64. Silva J, Garcia V, Rodriguez M et al. Analysis of exosome release and its prognostic value in human colorectal cancer. Genes Chromosomes Cancer. 2012; 51(4): 409-18.
65. Chiba M, Kimura M, Asari S. Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural anti-sense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines. Oncol Rep. 2012; 28(5): 1551-8.
66. Ogata-Kawata H, Izumiya M, Kurioka K et al. Circulating Exosomal microRNAs as Biomarkers of Colon Cancer. PLoS One. 2014; 9(4): e92921.
67. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G. Haemolysis during sample preparation alters microRNA content of plasma. PloS One. 2011; 6(9): e24145.
68. Hu J, Wang Z, Liao B-Y et al. Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients. Int J Cancer. 2014 doi: 10.1002/ijc.28757.
69. McDermott AM, Kerin MJ, Miller N. Identification and validation of miRNAs as endogenous controls for RQ-PCR in Blood Specimens for Breast Cancer Studies. PLoS One. 2013; 8(12): e83718.
70. MacLellan SA, MacAuley C, Lam S, Garnis C. Pre-profiling factors influencing serum microRNA levels. BMC Clin Pathol. 2014; 14(27): eCollection2014.